ストックスクリーナーアプリを入手
47.54
0.83%
0.39
アフターアワーズ：
47.51
-0.03
-0.06%
Bristol Myers Squibb Co (BMY) 最新ニュース
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire Inc.
BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Yahoo Finance
October 31st Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? - Yahoo Finance
Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal - Yahoo Finance
Ascent Group LLC Boosts Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Graham Capital Management L.P. Invests $568,000 in Bristol Myers Squibb Company $BMY - MarketBeat
United Services Automobile Association Has $12.60 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52% - MSN
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know - Yahoo Finance
BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy - MSN
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC - FirstWord Pharma
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - The Manila Times
BioNTech, Bristol Myers present interim data from a Phase 2 pumitamig trial - TipRanks
BioNTech and Bristol Myers Squibb Announce Encouraging Phase 2 Data for Pumitamig Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer - Quiver Quantitative
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose - Fierce Biotech
BioNTech and Bristol Myers Squibb amend partnership for BNT327 with $1.5 billion upfront payment - Investing.com India
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Purchased by Baird Financial Group Inc. - MarketBeat
What is Bristol Myers Squibb Company s debt to equity ratioWeekly Earnings Recap & Free Accurate Trade Setup Notifications - خودرو بانک
Is Bristol-Myers Squibb (BMY) a Value Trap or a Sleeping Giant in Biopharma? - AInvest
Short interest data insights for Bristol Myers Squibb Company Equity RightJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Using data tools to time your Bristol Myers Squibb Company exitGap Down & Fast Entry and Exit Trade Plans - Newser
Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug - BioPharma Dive
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Split 3rd Circ. Rejects Janssen, Bristol Myers Pricing Appeal - Law360
Top chart patterns to watch in Bristol Myers Squibb CompanyMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
J&J, Bristol Myers Lose Bid to Revive Suit Over Drug Price Talks - Bloomberg Law News
How Is Bristol-Myers’ Stock Performance Compared To Other Pharma Stocks? - Barchart.com
Canada Pension Plan Investment Board Sells 1,552,813 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Not As Cheap As It Might Seem (NYSE:BMY) - Seeking Alpha
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE? - Yahoo Finance
Combining machine learning predictions for Bristol Myers Squibb CompanyPortfolio Update Report & Expert Curated Trade Ideas - Newser
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
What is Bristol Myers Squibb Company s revenue forecastQuarterly Performance Summary & Reliable Entry Point Trade Alerts - خودرو بانک
Can machine learning forecast Bristol Myers Squibb Company Equity Right recoveryEarnings Recap Report & Technical Confirmation Trade Alerts - Newser
Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital - MSN
Is it time to cut losses on Bristol Myers Squibb Company Equity RightInsider Buying & Stepwise Trade Signal Guides - Newser
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
BMS’ WEE1 degrader BMS-986463 as a pan-cancer approach - BioWorld MedTech
B. Metzler seel. Sohn & Co. AG Grows Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Key resistance and support levels for Bristol Myers Squibb Company2025 Key Lessons & Step-by-Step Trade Execution Guides - Newser
Visual trend scoring systems applied to Bristol Myers Squibb Company Equity RightM&A Rumor & Low Risk Entry Point Tips - Newser
Risk vs reward if holding onto Bristol Myers Squibb Company Equity RightEarnings Growth Report & Growth Focused Stock Pick Reports - Newser
Long term hold vs stop loss in Bristol Myers Squibb Company Equity Right2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Bristol Myers Squibb Company Equity Right’s volatility index tracking explained2025 Market Outlook & Risk Managed Investment Signals - Newser
BMO Capital Maintains a Hold on Bristol-Myers Squibb (BMY) - Insider Monkey
How to interpret RSI for Bristol Myers Squibb Company stockEarnings Risk Report & Fast Gain Stock Tips - Newser
Bristol-Myers Squibb (NYSE:BMY) Receives FDA Breakthrough Therapy Designation for Lung Cancer Drug - Insider Monkey
Using data tools to time your Bristol Myers Squibb Company Equity Right exit2025 Key Lessons & Reliable Breakout Forecasts - Newser
Investors three-year losses continue as Bristol-Myers Squibb (NYSE:BMY) dips a further 3.2% this week, earnings continue to decline - Yahoo Finance
1.04%
0.13%
大文字化:
|
ボリューム (24 時間):